Press releases

Month Year

Email alerts

May 23, 2013

Medtronic CoreValve® System Gains First Approval for Transcatheter Valve-In-Valve Procedures

Replacing Degenerated Surgical Valves with CoreValve Results in Significant Hemodynamic Improvements for Patients

MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received Conformité Européenne (CE) Mark for valve-in-valve (VIV) procedures using the CoreValve® and CoreValve®...
May 23, 2013

Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity(TM) Renal Denervation System for Treatment-Resistant Hypertension

Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S.

MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal...
May 21, 2013

Medtronic Finds TAVI with CoreValve® System Cost Effective for Treating Patients with Severe Aortic Stenosis

EuroPCR Presentation of "Real World" ADVANCE Study Confirms Economic Value of Novel Self-Expanding Valve in Patients Unable to Undergo Surgery

PARIS -- May 21, 2013 -- Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. (NYSE: MDT) today unveiled the results of a cost-effectiveness model comparing...
May 21, 2013

Medtronic Announces Data From Largest Real-World Patient Population Confirm Strong Safety Profile and Clinical Efficacy of Renal Denervation with the Symplicity(TM) System

First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting

MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation...
May 21, 2013

Medtronic's Multi-Electrode, Simultaneously Firing Renal Denervation Catheter Shows Reduced Procedure Times While Demonstrating Significant Blood Pressure Reduction

Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time

MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation...

Show per page